Pharmaceutical companies operate in one of the most capital-intensive, high-stakes environments in business. When capital dries up, a clinical program fails, or a patent cliff arrives ahead of schedule, the path forward gets complicated fast — and the window to act narrows with it.
Having worked extensively in this space, what I’ve found is that the companies that navigate these moments well aren’t always the ones with the best science. They’re the ones with the right leadership, engaged boards, and a clear view of their options before a crisis forces the issue.
What’s Driving Pharma Companies into Distress
The pressures facing pharmaceutical companies today are compounding. No single factor is creating the distress we’re seeing. It’s the intersection of several.
The financing landscape has become significantly more difficult. Capital that was once available to early and mid-stage companies is harder to secure and more expensive when it is. Failed clinical development programs — an inherent risk in this industry — can be catastrophic when the balance sheet doesn’t have the depth to absorb the setback.
Patent challenges and generic competition continue to erode revenue faster than many management teams anticipate. Combined with aging product portfolios that require significant capital to refresh, companies can find themselves needing to invest heavily at precisely the moment their financial flexibility is most constrained.
Add supply chain disruption and the emerging pressure of tariffs, and what might have been a manageable challenge a few years ago can become a genuine crisis today.
What Makes Pharmaceutical Restructuring Unique
Restructuring a pharmaceutical company is not like restructuring a retailer or a manufacturer. Two things make it genuinely different.
First, many companies in distress are carrying balance sheets that simply can’t support the cost and duration of a restructuring process. Keeping operations running, maintaining regulatory compliance, and preserving the value of clinical assets all require capital — and that requirement doesn’t pause because the business is under financial pressure.
The timelines to value-creating milestones in this industry are long. A therapy in development may be years from generating meaningful revenue. That creates a real problem that most advisors underestimate.
How Do You Know if a Company Can Be Turned Around?
This is the question that matters most, and it requires honest assessment. Not optimism.
Management — Is the right team in place? More specifically, is the team nimble enough to do two things simultaneously: harvest value from therapies already on the market while continuing to develop new treatments? That dual focus is rare and genuinely difficult to execute. When it exists, it’s a significant positive signal.
Investor willingness — Are the company’s existing investors — or potential new ones — prepared to commit capital to either develop additional medicines or pursue acquisitions that strengthen the pipeline? Without that commitment, the options narrow quickly.
A credible growth strategy — Has leadership presented a strategy grounded in the company’s actual assets, realistic about timelines, and specific about how value will be created? Not a presentation. A strategy. If the answer is no, that tells you something important about what comes next.
What Boards Should Be Looking For
Boards play a critical role in pharmaceutical companies and in my experience, they are often not as engaged as the situation demands.
Financial discipline has to be maintained and measured, not assumed. Boards should be receiving meaningful financial metrics regularly and holding management accountable to both financial and development goals. If that accountability structure isn’t in place, it needs to be built before the pressure arrives.
Key man turnover deserves serious attention. Excessive leadership departure is one of the clearest early warning signs that something is wrong beneath the surface. Boards that treat it as a routine HR matter miss the underlying signal — and often pay for that later.
Boards also need to stay current on competitive dynamics, regulatory changes, and capital market conditions. The pharmaceutical environment moves quickly. A board operating on stale information cannot provide meaningful oversight.
And perhaps most importantly, boards need to be actively considering alternative strategies and assessing their feasibility. Not as a last resort — as an ongoing responsibility. The companies that come through difficult periods are almost always the ones where someone was already asking the hard questions before a crisis forced the conversation.
What Makes the Difference
The pharmaceutical industry will continue to generate restructuring situations. Margins are under pressure, development timelines are long, and the capital environment is unforgiving.
What makes the difference is leadership that understands the options, boards that stay engaged, and advisors who bring real experience to the work. Not just a process.